59338-0775-10FERAHEME 510 mg/17 mL, 10 vials Diagnosis codes (ICD-10)4 D50.0 Blood loss (chronic) D50.1 Sideropenic dysphagia D50.8 Poor iron absorption D50.9 Iron deficiency anemia, unspecified Confirm iron deficiency before using the following codes:
FERAHEME product and administration codes HCPCS1 Injection, ferumoxytol, for treatment of IDA, 1 mg Q0138non-ESRD use OR Q0139ESRD on dialysis Drug administration CPT®codes2† 96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour National Drug Codes (NDC)3‡
Medicaid covers appropriate administration codes when billed with Q0138, Q0139, J1750, J1756, or J2916 on the same day of service. • Feraheme® (ferumoxytol) Injection for intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Medicaid and NCHC shall cover ferumoxytol only for the following FDA-Approved Indications: Iron deficiency anemia in adult beneficiaries who are hemodialysis dependent with chronic kidney disease (HDD-CKD) Iron deficiency anemia in adult beneficiaries who are non-dialysis dependent with chronic kidney disease (NDD-CKD), and
FERAHEME is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or. • who have chronic kidney disease (CKD) Please see additional Important Safety Information throughout.
Feraheme will be given to you into your vein by intravenous (IV) infusion over at least 15 minutes by your healthcare provider. You will receive Feraheme in 2 doses 3 to 8 days apart. Your healthcare provider will watch you during and for at least 30 minutes after you receive Feraheme.
96374 is the code for the physician to administer the IV.
Feraheme (ferumoxytol) Injection is a type of iron used to treat iron deficiency anemia in people with chronic kidney disease. Anemia is a lack of red blood cells caused by having too little iron in the body.
Ferumoxytol (Other Names: Feraheme®) | UPMC Hillman Cancer Center.
Ferumoxytol is given by a health care professional. It is given by slow injection into a vein over at least 15 minutes, usually in a clinic or hospital. Treatment involves receiving two doses of ferumoxytol, given 3 to 8 days apart. It may be given during dialysis.
Medicare does not have a National Coverage Determination (NCD) for Feraheme® (ferumoxytol) or for Injectafer® (ferric carboxymaltose).
When billing your Medicare Advantage members for Intravenous Iron Therapy, you must use dual diagnoses codes - one code from the anemia codes and one from the kidney disease codes - from National Coverage Determination (NCD) 110.10 when billing procedure code J1756 or J2916.
ICD-10 code D50. 9 for Iron deficiency anemia, unspecified is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Ferumoxytol injection is an iron replacement product that is used to treat iron deficiency anemia (not enough iron in the blood) in patients with chronic kidney disease (CKD) and in patients unable to take oral iron or who had taken oral iron in the past but did not work well.
Ferumoxytol is used to treat iron deficiency anemia (a lack of red blood cells caused by having too little iron in the body). Ferumoxytol injection is used in people with chronic kidney disease, or in people unable to take oral iron (by mouth) or who have not responded well to oral iron.
Feraheme is in a class of medicines called IV iron replacement products. It is used to treat iron-deficiency anemia―a condition in which there is a lower than normal number of oxygen-carrying red blood cells because of too little iron.